Key statistics
On Friday, Lumos Pharma Inc (LUMO:NMQ) closed at 4.31, -5.80% below its 52-week high of 4.58, set on Oct 23, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.36 |
---|---|
High | 4.40 |
Low | 4.30 |
Bid | 4.28 |
Offer | 4.40 |
Previous close | 4.33 |
Average volume | 112.59k |
---|---|
Shares outstanding | 8.65m |
Free float | 5.82m |
P/E (TTM) | -- |
Market cap | 37.45m USD |
EPS (TTM) | -4.29 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
- Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201’s Unique Pulsatile Mechanism of Action
- Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62ⁿᵈ Annual ESPE Meeting 2024
- Lumos Pharma Enters into Definitive Merger Agreement with Double Point Ventures to Go Private via a Tender Offer of $4.25 Cash per Share Plus Contingent Value Rights (CVR)
- Lumos Pharma Announces Abstract Accepted for Oral Presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, APPES 2024
- Lumos Pharma Announces Abstract Accepted for Presentation at September Medical Meeting, SLEP 2024
- Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference
- Lumos Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Development Update
- Lumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024
- Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024
- Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024
More ▼